German pharma major Bayer today announced top-line results of the Phase III study OASIS 4 investigating elinzanetant as ...

MitoRx Therapeutics strengthens its leadership with the appointments of Lubor Gaal as chief business officer and Stacey ...

Intelligence provider Clarivate has released the 12th annual Drugs to Watch report, a guide to the therapies poised to ...

Sanofi reports positive Phase III results for a subcutaneous version of Sarclisa in relapsed or refractory multiple myeloma.

Swiss oncology-focused Araris Biotech developing next-generation antibody drug conjugates (ADCs), today announced a research ...

UK-based Alchemab Therapeutics, a biopharma seeking to identify and develop naturally occurring therapeutic antibodies from ...

UK headquartered Verdiva Bio Limited today announced its launch as a clinical-stage biopharmaceutical company focused on ...

Italy-based Newron Pharmaceuticals (SIX: NWRN, XETRA: NP5), a biopharma developing therapies for diseases of the central and ...

Cambridge, USA-based biotech Sunbird Bio, which is developing proprietary blood-based technologies to improve diagnosis and ...

AstraZeneca's Lynparza receives NICE approval for treating advanced breast cancer in England and Wales, backed by OlympiAD ...

MaaT Pharma reports positive Phase III results for MaaT013, its microbiome-based therapy for gastrointestinal GvHD, achieving ...

German family-owned pain focused drugmaker Grünenthal announced today that Prof Dr Uli Brödl will assume the role of chief ...